{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:20Z","timestamp":1792787300177,"version":"4.5.0"},"reference-count":72,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases","award":["T32 AI162624"],"award-info":[{"award-number":["T32 AI162624"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["21B03"],"award-info":[{"award-number":["21B03"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using the mouse IL-2\/CD25 fusion protein (mIL-2\/CD25) at a high dose (HD) and anti-PD-1 checkpoint blockade, with the CT26 and MC38 colon carcinomas as models, the current study investigated how antitumor responses occurred when regulatory T cells (Tregs) are also a target of HD mIL-2\/CD25. Single-cell RNA sequencing (scRNA-seq) and T-cell receptor (TCR) repertoire analysis of tumor-associated immune cells were used to identify how combination therapy reshaped the tumor microenvironment (TME). These data were cross-referenced with published datasets to (1) corroborate TCR specificity and (2) identify how CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell differentiation is affected by different IL-2\/PD-1 strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here, we show that effective antitumor immunity by the combination therapy is a result of HD mIL-2\/CD25-dependent reprogramming of CD8\n                      <jats:sup>+<\/jats:sup>\n                      tumor-specific T cells that increases their function and supports their expansion within the TME, the latter also shaped by PD-1 blockade. This therapy supports antitumor responses by chemokines and inflammatory cytokines that selectively favor the migration of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells but not Tregs deep within the tumor. After HD mIL-2\/CD25 treatment, Tregs within the TME showed impaired downstream IL-2R signaling, reflected by failed upregulation of forkhead box P3 and CD25, impaired development into effector Tregs, and enhanced cell death, the latter which likely offsets Treg proliferation. Many similarities were noted after direct comparison of these scRNA-seq findings with another study where IL-2 activity was targeted to PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Notably, HD mIL-2\/CD25 and anti-PD-1 combination promotes effector and \u2018stem-like\u2019 CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell subsets, perhaps even to a greater extent than the PD-1-targeted IL-2 strategy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The efficient differentiation of exhausted CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells into highly functional cells and the resulting potent antitumor responses by HD mIL-2\/CD25 plus anti-PD-1 suggest that this approach may augment durable response rates more than currently achieved with checkpoint blockade monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015104","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:55:23Z","timestamp":1790693723000},"page":"e015104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["IL-2\/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8\n                    <sup>+<\/sup>\n                    T cells while restraining regulatory T-cell accumulation"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03635983","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04410445","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03729245","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kathryn M","family":"LaPorte","sequence":"first","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"P\u00f5der","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Dalzell","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Serafini","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro V","family":"Villarino","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-0434","authenticated-orcid":false,"given":"Thomas R","family":"Malek","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092907551001000_14.9.e015104.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"2026092907551001000_14.9.e015104.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"2026092907551001000_14.9.e015104.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w"},{"key":"2026092907551001000_14.9.e015104.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.07.022"},{"key":"2026092907551001000_14.9.e015104.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00680-w"},{"key":"2026092907551001000_14.9.e015104.6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153604","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"2026092907551001000_14.9.e015104.7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"2026092907551001000_14.9.e015104.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05257-0"},{"key":"2026092907551001000_14.9.e015104.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006611","article-title":"Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells","volume":"11","author":"LaPorte","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092907551001000_14.9.e015104.10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat Cancer"},{"key":"2026092907551001000_14.9.e015104.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101747","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026092907551001000_14.9.e015104.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800907"},{"key":"2026092907551001000_14.9.e015104.13","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0186"},{"key":"2026092907551001000_14.9.e015104.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100078"},{"key":"2026092907551001000_14.9.e015104.15","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0482"},{"key":"2026092907551001000_14.9.e015104.16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-020-02722-5","article-title":"Sustained IL-2R signaling of limited duration by high-dose mIL-2\/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity","volume":"70","author":"Hernandez","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026092907551001000_14.9.e015104.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002865","article-title":"High-dose IL-2\/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity","volume":"9","author":"Hernandez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026092907551001000_14.9.e015104.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01179-1"},{"key":"2026092907551001000_14.9.e015104.19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21135"},{"key":"2026092907551001000_14.9.e015104.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.057"},{"key":"2026092907551001000_14.9.e015104.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701188"},{"key":"2026092907551001000_14.9.e015104.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00303-x"},{"key":"2026092907551001000_14.9.e015104.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.7682337"},{"key":"2026092907551001000_14.9.e015104.24","doi-asserted-by":"publisher","DOI":"10.1038\/nature04651"},{"key":"2026092907551001000_14.9.e015104.25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4617"},{"key":"2026092907551001000_14.9.e015104.26","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.18632\/oncotarget.3205","article-title":"Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration","volume":"6","author":"Zumwalt","year":"2015","journal-title":"Oncotarget"},{"key":"2026092907551001000_14.9.e015104.27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1393598","article-title":"CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFN\u03b3","volume":"7","author":"Allen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026092907551001000_14.9.e015104.28","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.290"},{"key":"2026092907551001000_14.9.e015104.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108944"},{"key":"2026092907551001000_14.9.e015104.30","first-page":"5399","article-title":"Macrophages in skin melanoma-the key element in melanomagenesis","volume":"15","author":"Pieniazek","year":"2018","journal-title":"Oncol Lett"},{"key":"2026092907551001000_14.9.e015104.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2326"},{"key":"2026092907551001000_14.9.e015104.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-020-00589-8","article-title":"CCL2\/CCR2 signaling in cancer pathogenesis","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun Signal"},{"key":"2026092907551001000_14.9.e015104.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.950213","article-title":"CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment","volume":"13","author":"Lou","year":"2022","journal-title":"Front Immunol"},{"key":"2026092907551001000_14.9.e015104.34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245795","article-title":"Lactate-Induced CCL8 in Tumor-Associated Macrophages Accelerates the Progression of Colorectal Cancer through the CCL8\/CCR5\/mTORC1 Axis","volume":"15","author":"Zhou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092907551001000_14.9.e015104.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(99)00004-1"},{"key":"2026092907551001000_14.9.e015104.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00476.x"},{"key":"2026092907551001000_14.9.e015104.37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.161.6.1575"},{"key":"2026092907551001000_14.9.e015104.38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.58.070189.004303"},{"key":"2026092907551001000_14.9.e015104.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(97)00021-X"},{"key":"2026092907551001000_14.9.e015104.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00167-4"},{"key":"2026092907551001000_14.9.e015104.41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi8217","article-title":"Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and function","volume":"8","author":"Spolski","year":"2023","journal-title":"Sci Immunol"},{"key":"2026092907551001000_14.9.e015104.42","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080939","article-title":"Transcriptional Regulation of Differentiation and Functions of Effector T Regulatory Cells","volume":"8","author":"Koizumi","year":"2019","journal-title":"Cells"},{"key":"2026092907551001000_14.9.e015104.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004747"},{"key":"2026092907551001000_14.9.e015104.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.042"},{"key":"2026092907551001000_14.9.e015104.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02104","article-title":"ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2026092907551001000_14.9.e015104.46","doi-asserted-by":"publisher","DOI":"10.1038\/ni1437"},{"key":"2026092907551001000_14.9.e015104.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.005"},{"key":"2026092907551001000_14.9.e015104.48","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1007\/s00018-017-2569-y","article-title":"Molecular mechanisms underlying Th1-like Treg generation and function","volume":"74","author":"Kitz","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"2026092907551001000_14.9.e015104.49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0066"},{"key":"2026092907551001000_14.9.e015104.50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44391-9","article-title":"FOXP3+ regulatory T cell perturbation mediated by the IFN\u03b3-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"2026092907551001000_14.9.e015104.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111248","article-title":"Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets","volume":"27","author":"Shouse","year":"2024","journal-title":"iScience"},{"key":"2026092907551001000_14.9.e015104.52","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2000099"},{"key":"2026092907551001000_14.9.e015104.53","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02769-y","article-title":"Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sj\u00f6gren\u2019s syndrome","volume":"24","author":"Keindl","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026092907551001000_14.9.e015104.54","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90113-2"},{"key":"2026092907551001000_14.9.e015104.55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.4.1879"},{"key":"2026092907551001000_14.9.e015104.56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.4.731"},{"key":"2026092907551001000_14.9.e015104.57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2444"},{"key":"2026092907551001000_14.9.e015104.58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9730"},{"key":"2026092907551001000_14.9.e015104.59","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/eji.201948433","article-title":"Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue-resident memory T cells against the AH1 rejection antigen","volume":"50","author":"Stringhini","year":"2020","journal-title":"Eur J Immunol"},{"key":"2026092907551001000_14.9.e015104.60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0134"},{"key":"2026092907551001000_14.9.e015104.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.07.007"},{"key":"2026092907551001000_14.9.e015104.62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142205"},{"key":"2026092907551001000_14.9.e015104.63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02987","article-title":"Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act","volume":"9","author":"Kalia","year":"2018","journal-title":"Front Immunol"},{"key":"2026092907551001000_14.9.e015104.64","doi-asserted-by":"publisher","DOI":"10.1016\/J.IT.2023.09.003\/ASSET\/94B18407-EFBC-4066-B52A-82ED670C9C48\/MAIN.ASSETS\/GR4.JPG"},{"key":"2026092907551001000_14.9.e015104.65","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79342","article-title":"Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2","volume":"12","author":"Tsyklauri","year":"2023","journal-title":"Elife"},{"key":"2026092907551001000_14.9.e015104.66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010465","article-title":"Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion","volume":"13","author":"Kilic","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026092907551001000_14.9.e015104.67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0565"},{"key":"2026092907551001000_14.9.e015104.68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"key":"2026092907551001000_14.9.e015104.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.11.005"},{"key":"2026092907551001000_14.9.e015104.70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4062"},{"key":"2026092907551001000_14.9.e015104.71","doi-asserted-by":"crossref","DOI":"10.3390\/bioengineering10010047","article-title":"Automatic Segmentation of Cervical Cells Based on Star-Convex Polygons in Pap Smear Images","volume":"10","author":"Zhao","year":"2022","journal-title":"Bioengineering (Basel)"},{"key":"2026092907551001000_14.9.e015104.72","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:55:27Z","timestamp":1790693727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015104"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015104","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}